SEGMENT INFORMATION

6 Months Ended

Jun. 30, 2026

Segment Reporting [Abstract]

SEGMENT INFORMATION

NOTE 13 - SEGMENT INFORMATION

The Company has one operating and reporting segment, that develops, manufactures and markets products for the treatment of carotid artery disease and other vascular disease, including the Company’s proprietary CGuard™ stent platform. The Company’s Chief Operating Decision Maker (“CODM”), who is the chief executive officer, evaluates the Company’s performance based on its internal reporting which is consistent with the presentation in the Company’s consolidated financial statements. Accordingly, our CODM uses consolidated net loss to measure segment profit or loss, allocate resources, and assess performance.

The CODM examines, within each operational function, the employee salaries including the bonus and share based compensation. In addition, the CODM examines the clinical trials expenses within the research and development operations.

	Three months ended June 30,						Six months ended June 30,
	2026			2025			2026			2025
Revenues		1,771			1,778			5,169			3,307
Cost of Revenues:
Material and Labor		1,631			1,138			3,322			2,163
Other cost of revenues		302			327			849			539
Inventory write-off		612			-			1,085			-
Total Cost of Revenues		2,545			1,465			5,256			2,702
Research and development (R&D)
Payroll and Benefits		1,282			1,120			2,882			1,974
Share based compensation		435			645			610			1,314
Clinical trials		972			1,125			2,473			2,287
Other R&D		1,606			944			3,093			2,318
Total Research and development		4,295			3,834			9,058			7,893
Selling and marketing (S&M)
Payroll and Benefits		3,932			2,779			7,795			4,757
Share based compensation		543			595			1,124			812
Other S&M		746			798			1,482			1,353
Total Selling and marketing		5,221			4,172			10,401			6,922
General and administrative (G&A)
Payroll and Benefits		1,365			1,729			3,172			3,309
Share based compensation		1,177			1,920			2,466			3,700
Other G&A		1,613			1,677			3,239			3,260
Total General and administrative		4,155			5,326			8,877			10,269
Financial Income (expenses), net;		121			(132	)		410			162
Segment net loss		(14,324	)		(13,151	)		(28,013	)		(24,317	)